Synthon IP knowingly withheld Pfizer publications and other information it possessed to acquire its patents.

A court ruled against Synthon IP in a patent infringement case related to Pfizer’s hypertension drug, Norvasc. The Federal District Court in the Eastern District of Virginia found that Synthon IP obtained, by inequitable conduct, two U.S. patents covering a process and an intermediate compound used to make the active ingredient in the medication.

Pfizer intends to seek attorneys’ fees from Synthon.

Pfizer reported the court ruled that Synthon had knowingly failed to disclose to the U.S. Patent Office Pfizer publications and other information it had in its possession that described the process Synthon sought to patent.

Previous articleGalapagos Licenses its Obesity and Diabetes Discovery Technology for Upwards of Euro 27.77M
Next articleStanford-Led Study Closes in on Severe Depression Gene